Norton P. Peet, Ph.D., Co-Chair
Dr.
Peet
is
an
International
R&D
Consultant,
in
which
capacity
he
provides
guidance
and
direction
to
industrial
and
academic
organizations
on
drug
discovery
and
development
strategies,
based
on
his
extensive
experience
in
the
pharmaceutical
industry.
Dr.
Peet
currently
serves
as
the
Chief
Scientific
Officer
for
Chicago
BioSolutions,
a
newly
formed
drug
discovery
company.
In
prior
positions,
Dr.
Peet
was
Head
of
Medicinal
Chemistry
at
Microbiotix,
where
he
designed
the
chemistry
for
all
internal
and
external
research
proposals.
Dr.
Peet
is
an
organic
chemist
by
training
(U
Nebraska,
MIT)
and
has
spent
much
of
his
career
in
big
pharma,
with
the
string
of
companies
that
led
to
Aventis
(now
Sanofi).
When
he
left
Aventis
in
2000,
he
was
Head
of
Medicinal
Chemistry
and
Distinguished
Scientist.
He
joined
the
executive
team
at
ArQule
as
Vice
President
of
Discovery
Alliances,
where
he
built
a
multidisciplinary
Drug
Discovery
Group.
In
2002,
he
became
the
CEO
of
Aurigene
Discovery
Technologies,
a
drug
discovery
company,
and
built
laboratories
in
Boston
(Lexington)
and
Bangalore
(India).
Dr.
Peet
has
authored
175
journal
articles
and
70
US
patents,
and
has
contributed
to
25
awarded
grant
applications.
He
has
organized
numerous
international
symposia
and
serves
on
several
editorial
and
scientific
advisory
boards.
Kevin
R.
Woller,
Ph.D.,
Co-Chair
Dr.
Woller
is
currently
a
Chemistry
Group
Leader
with
the
biopharmaceutical
company
AbbVie
where
he
has
spent
the
last
15
year
(10
years
as
Abbott
Laboratories)
leading
early
stage
drug
discovery
efforts.
Prior
to
Abbott/AbbVie,
he
spent
nearly
5
years
with
ArQule,
a
biotech
focused
on
utilization
of
parallel
organic
synthesis
in
drug
discovery.
Dr.
Woller
is
a
co-inventor
on
16
US
Patents
covering
two
development
candidates,
one
Phase
I
compound
(Begacestat),
one
Phase
III
compound
(Upadacitinib)
and
two
marketed
drugs
(Ombitasvir
&
Pibrentasvir).
A
native
of
Minnesota,
he
received
his
undergraduate
degree
from
Minnesota
State-Mankato,
PhD
from
the
University
of
Nebraska-Lincoln
with
Pat
Dussault,
and
did
postdoctoral
research
in
the
labs
of
Bruce
Ganem
at
Cornell.
Chad
J.
Briscoe,
Ph.D.
Dr.
Briscoe
received
a
BS
in
Chemistry
from
Alma
College,
an
MS
from
the
University
of
Michigan
and
his
PhD
from
the
University
of
Nebraska
on
studies
of
protein
binding
affinities
via
LC-MS/MS
and
computer
simulation.
His
20+
year
career
in
drug
development
has
been
focused
in
the
field
of
regulated
bioanalysis
to
support
clinical
and
non-‐clinical
trials.
Chad
is
currently
the
Executive
Director
of
Bioanalytical
Science
at
PRA.
He
was
previously
the
Director
of
Bioanalytical
Operations
at
MDS-‐Pharma.
He
has
become
well
known
in
the
bioanalytical
community
on
such
diverse
issues
as
the
use
of
advanced
LC-‐MS/MS
technology
applied
to
high-‐throughput
analysis,
system
suitability
in
high-‐throughput
LC-MS/MS
and
bioanalytical
software
validation.
Chad
has
served
as
chair
of
the
Global
Bioanalysis
Consortium's
Analytical
Instrument
Qualification
Team
and
as
editor
for
the
Management
and
Leadership
column
in
the
journal
Bioanalysis.
Chad
was
previously
with
Dow
Corning.
Ryan
E.
Hartung,
Ph.D.
Dr.
Hartung
is
currently
Senior
Research
Investigator,
at
Icagen
(Tuscon,
AZ).
Ryan
is
a
native
of
Nebraska,
where
he
performed
undergraduate
research
as
part
of
his
BS
Chemistry
studies
with
David
Berkowitz.
Ryan
pursued
his
PhD
in
synthetic
organic
chemistry
at
the
Ohio
State
University,
under
the
tutelage
of
Leo
Paquette,
generating
twelve
publications
during
his
tenure
there.
He
began
his
career
in
pharma
as
a
medicinal
chemist
at
Sanofi- Aventis
(Bridgewater,
New
Jersey).
There
Ryan
was
primarily
engaged
in
and
led
hit-to-candidate
projects
in
the
CNS
portfolio.
He
then
relocated
to
Sanofi-Aventis/Tucson,
where
he
continued
to
lead
multiple
early
stage
projects.
In
summer
2016,
the
Tucson
site
was
acquired
by
Icagen,
with
a
particular
interest
in
hit-to-lead
candidate
advancement.
Ryan
Hartung
is
well
versed
in
early
stage
research,
SAR
(structure
to
activity
relationship),
medicinal
chemistry,
solid
phase
synthesis,
combinatorial
library
approaches
and
protein
synthesis.
Eve
Elizabeth
Slater,
MD
Dr.
Eve
Slater
is
currently
Professor
of
Clinical
Medicine
at
Columbia
University
College
of
Physicians
and
Surgeons,
where
she
has
taught
in
various
positions
since
1983.
Dr.
Slater
has
worked
in
clinical
and
laboratory
research,
developed
life-saving
drugs,
managed
regulatory
affairs
at
one
of
the
largest
pharmaceutical
laboratories,
and
guided
health
policy
decisions
affecting
the
nation
as
the
U.S.
Assistant
Secretary
of
Health
and
Human
Services.
From
1977
through
1982,
while
serving
as
chief
of
the
hypertension
unit
at
Massachusetts
General
and
as
assistant
professor
of
medicine
at
Harvard
Medical
School,
Dr.
Slater
pursued
research
on
hypertension
and
diseases
of
the
aorta.
In
1983,
Dr.
Slater
joined
Merck
Research
Laboratories
as
senior
director
of
biochemical
endocrinology,
where
she
guided
teams
of
molecular
biologists
in
researching
receptors,
endocrinology,
and
arteriosclerosis
(the
formation
of
calcium,
fats,
and
cholesterol
deposits
in
blood
vessels).
She
was
promoted
to
vice
president
of
their
Clinical
and
Regulatory
Development
in
1990
and
senior
vice
president
in
1994,
becoming
the
first
woman
to
attain
those
ranks.
Continuing
to
teach
as
her
research
career
progressed,
Dr.
Slater
remained
an
adjunct
associate
clinical
professor
of
medicine
at
her
alma
mater,
Columbia
University
College
of
Physicians
and
Surgeons,
from
1983
through
2002.
In
2001,
President
George
W.
Bush
nominated
Dr.
Slater
as
assistant
secretary
for
health,
and
she
was
confirmed
in
January
2002.
In
this
role,
which
she
held
until
February
2003,
she
oversaw
the
United
States
Public
Health
Service,
including
eight
health
agency
divisions
and
the
Commissioned
Corps,
which
includes
more
than
6,000
uniformed
health
professionals.
During
her
service,
special
emphasis
was
given
to
bioterrorism,
the
protection
of
human
subjects,
health
care
reform,
women's
health,
care
of
the
elderly,
and
HIV/AIDS.
Christie
M.
Orschell,
Ph.D.
Dr.
Christie
Orschell
is
Professor
of
Medicine
in
the
Division
of
Hematology
and
Medicine
at
the
Indiana
University
School
of
Medicine
(IUSOM).
She
is
a
member
of
the
Hematopoiesis
and
Hematology
Malignancies
Research
Program
at
IU.
Dr.
Orschell
obtained
her
BS
in
Medical
Technology
at
Indiana
University
and
her
PhD
in
the
Department
of
subsequently
completed
her
PhD
in
the
Department
of
Pharmacology
and
Toxicology
at
IUSOM.
Dr.
Orschell
is
an
internationally
recognized
authority
in
radiation
biology,
particularly
in
the
development
of
animal
models
for
the
study
of
the
effects
of
radiation
on
mammalian
systems,
including
for
the
study
of
acute
radiation
syndrome
(ARS).
Dr.
Orschell
is
also
an
expert
on
establishing
Good
Laboratory
Practice
(GLP)
compliant
laboratories
in
compliance
with
FDA
GLP
regulations,
and
has
lectured
on
these
topics
extensively.
Dr.
Orschell
is
a
member
of
the
International Society for Experimental
Hematology, the American Society of Hematology, the Radiation Research Society and the
European Radiation Research Society and has served on numerous federal review panels,
particularly at NIH and NASA.
General
John
S.
Parker,
M.D. (retired)
Dr.
Parker
is
a
physician
and
just
retired
after
seven
years
as
member
and
Chairman
of
the
National
Preparedness
and
Response
Science
Board
–
also
known
as
the
National
Biodefense
Science
Board.
He
is
a
cardiothoracic
surgeon
and
a
retired
Major
General
from
the
Army.
His
39
years
in
the
Army
saw
him
practice
surgery,
teach
and
manage
very
large
healthcare
and
research
institutions.
He
is
an
associate
Professor
of
Surgery
at
the
Uniformed
Services
School
of
Medicine.
He
served
as
the
Assistant
Surgeon
General
of
the
Army.
Dr.
Parker
has
broad
experience
in
managing
or
being
significantly
involved
in
disasters
such
as
Chernobyl,
Beirut
bombing,
USS
Stark
incident,
Amerithrax
(Senate
office
building
exposure
to
Anthrax)
and
the
Berlin
Disco
Bombing.
His
last
assignment
in
the
Army
was
as
Commanding
General
of
the
US
Army
Medical
Research
and
Materiel
Command
and
Fort
Detrick.
Following
retirement,
he
worked
for
SAIC
–
now
Leidos
supporting
work
for
WMD
defense
and
significant
work
in
the
Biological
threat
reduction
area.
Thomas
J.
MacVittie,
Ph.D.
Dr.
MacVittie
is
recognized
internationally
as
an
expert
on
the
effects
of
radiation
on
the
hematopoietic
and
gastrointestinal
systems
in
large
animal
models
and
their
treatment,
in
vivo,
with
supportive
care
and
selected
organ-specific
medical
countermeasures
against
acute
and
delayed
effects
of
acute
radiation
exposure.
He
earned
M.S.
and
Ph.D.
degrees
in
radiation
biology
at
the
State
University
of
New
York
(SUNY)
at
Buffalo
and
has
more
than
40
years
of
experience
as
a
radiobiologist
in
the
field
of
experimental
hematology.
He
has
published
184
peer-reviewed
manuscripts
and
47
chapters
in
books
or
proceedings.
He
has
co-edited
5
books
published
from
international
meetings
organized
on
radiation
effects
and
treatment
of
the
ARS.
Dr.
MacVittie
has
served
as
an
advisor
to
the
WHO
Collaborating
Centers
in
Radiation
Emergency
Medical
Preparedness
and
Assistance
and
as
a
member
of
NATO
Radiation
Research
Study
groups.
He
was
a
member
of
a
Task
Group
for
the
International
Council
on
Radiation
Protection
entitled
“Radiation
Effects
on
Normal
Tissue”,
the
CDC
Strategic
National
Stockpile
Radiation
Working
Group,
the
American
Society
of
Hematology,
the
International
Society
of
Experimental
Hematology
and
Radiation
Research.
Dr.
MacVittie
has
served
on
the
editorial
board
of
the
journal
Experimental
Hematology
and
is
currently
a
member
of
the
editorial
board
of
the
journal
Stem
Cells
and
serves
as
an
ad
hoc
reviewer
for
numerous
journals
and
National
Institutes
of
Health
and
Department
of
Defense
grants
and
contracts.
Dr.
MacVittie
was
invited
by
the
Secretary,
U.S.
Department
of
Health
and
Human
Services,
to
serve
on
the
inaugural
National
Biodefense
Science
Board
Federal
Advisory
Committee
from
2007
to
2011.
